JCR Pharmaceuticals Co Ltd (4552) - Financial and Strategic SWOT Analysis Review
Description
JCR Pharmaceuticals Co Ltd (4552) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
JCR Pharmaceuticals Co Ltd (JCR Pharma) is a biopharmaceutical company. It produces, purchases, and sells medical drugs, pharmaceutical raw materials and regenerative medicine products. The company's product portfolio includes Growject for growth hormone deficiency and short stature; Izcargo for Mucopolysaccharidosis type II; Agalsidase Beta BS IV Infusion for Fabry disease; Temcell HS Injection for acute graft-versus-host disease; and Epoetin and Darbepoetin Alfa BS injections for managing renal anemia. Its R&D pipeline focuses on advanced therapeutic solutions using its proprietary J-Brain Cargo and J-MIG System technologies. JCR Pharma is headquartered in Ashiya-Shi, Hyogo, Japan.
JCR Pharmaceuticals Co Ltd Key Recent Developments
Oct 07,2025: JCR Pharmaceuticals Enhances AAV Gene Therapy Delivery to CNS and Muscle
Sep 19,2025: JCR Pharmaceuticals and Alexion Reach Key Milestone in Collaborative Neurodegenerative Research
Jul 16,2025: Acumen and JCR partner on brain delivery therapy for Alzheimer's
Jul 15,2025: JCR Pharmaceuticals Selected for Japan’s Regenerative Medicine CDMO Subsidy Program
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note:Some sections may be missing if data is unavailable for the company
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
JCR Pharmaceuticals Co Ltd (JCR Pharma) is a biopharmaceutical company. It produces, purchases, and sells medical drugs, pharmaceutical raw materials and regenerative medicine products. The company's product portfolio includes Growject for growth hormone deficiency and short stature; Izcargo for Mucopolysaccharidosis type II; Agalsidase Beta BS IV Infusion for Fabry disease; Temcell HS Injection for acute graft-versus-host disease; and Epoetin and Darbepoetin Alfa BS injections for managing renal anemia. Its R&D pipeline focuses on advanced therapeutic solutions using its proprietary J-Brain Cargo and J-MIG System technologies. JCR Pharma is headquartered in Ashiya-Shi, Hyogo, Japan.
JCR Pharmaceuticals Co Ltd Key Recent Developments
Oct 07,2025: JCR Pharmaceuticals Enhances AAV Gene Therapy Delivery to CNS and Muscle
Sep 19,2025: JCR Pharmaceuticals and Alexion Reach Key Milestone in Collaborative Neurodegenerative Research
Jul 16,2025: Acumen and JCR partner on brain delivery therapy for Alzheimer's
Jul 15,2025: JCR Pharmaceuticals Selected for Japan’s Regenerative Medicine CDMO Subsidy Program
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note:Some sections may be missing if data is unavailable for the company
Table of Contents
53 Pages
- Section 1 - About the Company
- JCR Pharmaceuticals Co Ltd - Key Facts
- JCR Pharmaceuticals Co Ltd - Key Employees
- JCR Pharmaceuticals Co Ltd - Major Products and Services
- JCR Pharmaceuticals Co Ltd - History
- JCR Pharmaceuticals Co Ltd - Company Statement
- JCR Pharmaceuticals Co Ltd - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Affiliate
- Section 2 – Company Analysis
- Company Overview
- JCR Pharmaceuticals Co Ltd - Business Description
- Product Category: Agalsidase Beta BS IV Infusion
- Performance
- Product Category: Contract Income
- Performance
- Product Category: Darbepoetin Alfa BS Injection
- Performance
- Product Category: Epoetin Alfa BS Injection
- Performance
- Product Category: Growject
- Performance
- Product Category: Izcargo
- Performance
- Product Category: Medical Devices
- Performance
- Product Category: Others
- Performance
- Product Category: Temcell HS Injection
- Performance
- R&D Overview
- JCR Pharmaceuticals Co Ltd - Corporate Strategy
- JCR Pharmaceuticals Co Ltd - SWOT Analysis
- SWOT Analysis - Overview
- JCR Pharmaceuticals Co Ltd - Strengths
- JCR Pharmaceuticals Co Ltd - Weaknesses
- JCR Pharmaceuticals Co Ltd - Opportunities
- JCR Pharmaceuticals Co Ltd - Threats
- JCR Pharmaceuticals Co Ltd - Key Competitors
- Section 3 – Company Financial Ratios
- Financial Ratios - Capital Market Ratios
- Financial Ratios - Annual Ratios
- Performance Chart
- Financial Performance
- Financial Ratios - Interim Ratios
- Financial Ratios - Ratio Charts
- Section 4 – Company’s Lifesciences Financial Deals and Alliances
- JCR Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
- JCR Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2019 to YTD 2025
- JCR Pharmaceuticals Co Ltd, Recent Deals Summary
- Section 5 – Company’s Recent Developments
- Oct 07, 2025: JCR Pharmaceuticals Enhances AAV Gene Therapy Delivery to CNS and Muscle
- Sep 19, 2025: JCR Pharmaceuticals and Alexion Reach Key Milestone in Collaborative Neurodegenerative Research
- Jul 16, 2025: Acumen and JCR partner on brain delivery therapy for Alzheimer's
- Jul 15, 2025: JCR Pharmaceuticals Selected for Japan’s Regenerative Medicine CDMO Subsidy Program
- Jul 09, 2025: JCR Pharma and Alexion partner on JUST-AAV gene therapy platform
- Jun 19, 2025: JCR Pharmaceuticals Announces Launch of Mucopolysaccharidosis (MPS Type II Disease Awareness Film Featured in The Next Frontier Series
- Jun 06, 2025: JCR Pharmaceuticals Announces Launch of New Global Website
- May 16, 2025: JCR Pharmaceuticals Presents Preclinical Gene Therapy Data that Demonstrate Promising CNS Uptake at American Society of Gene and Cell Therapy 28th Annual Meeting
- Jun 26, 2024: JCR Pharmaceuticals : Partial Correction - “Consolidated Financial Results for the Fiscal Year Ended March 31, 2024 (FY2023 ” (Japanese standard
- May 10, 2024: JCR Pharmaceuticals : Consolidated Financial Results for the Year ended March 31, 2024 (FY2023
- Section 6 – Appendix
- Methodology
- Ratio Definitions
- About GlobalData
- Contact Us
- Disclaimer
- List of Tables
- JCR Pharmaceuticals Co Ltd, Key Facts
- JCR Pharmaceuticals Co Ltd, Key Employees
- JCR Pharmaceuticals Co Ltd, Major Products and Services
- JCR Pharmaceuticals Co Ltd, History
- JCR Pharmaceuticals Co Ltd, Other Locations
- JCR Pharmaceuticals Co Ltd, Subsidiaries
- JCR Pharmaceuticals Co Ltd, Affiliate
- JCR Pharmaceuticals Co Ltd, Key Competitors
- JCR Pharmaceuticals Co Ltd, Ratios based on current share price
- JCR Pharmaceuticals Co Ltd, Annual Ratios
- JCR Pharmaceuticals Co Ltd, Annual Ratios (Cont...1)
- JCR Pharmaceuticals Co Ltd, Annual Ratios (Cont...2)
- JCR Pharmaceuticals Co Ltd, Interim Ratios
- JCR Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
- JCR Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2019 to YTD 2025
- JCR Pharmaceuticals Co Ltd, Recent Deals Summary
- Currency Codes
- Capital Market Ratios
- Equity Ratios
- Profitability Ratios
- Cost Ratios
- Liquidity Ratios
- Leverage Ratios
- Efficiency Ratios
- List of Figures
- JCR Pharmaceuticals Co Ltd, Performance Chart (2021 - 2025)
- JCR Pharmaceuticals Co Ltd, Ratio Charts
- JCR Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
- JCR Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2019 to YTD 2025
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
